Biotech - Spark Newswire

3 minute read

FDA
News

AstraZeneca Reports IMFINZI Showed Survival In Unresectable Stage 3 Lung Cancer With 43% Of Patients Surviving 5 Years

Today, 7:22 AM

Long-term data from PACIFIC Phase III trial at ASCO showed 33% of patients remained progression-free at five years Longest-ever survival reported in a Phase III immunotherapy trial in this setting WILMINGTON,

AZN

1 minute read

UPDATE: UK’s Medicines and Healthcare products Regulatory Agency Says Data For Neutralizing Antibodies Of Pfizer/BioNTech’s COVID-19 Vaccine Work At Same Levels As Seen In Adults Aged 16-25 Years

By Benzinga Newsdesk

Today, 7:22 AM

-Reuters

BNTX

1 minute read

UK’s Medicines and Healthcare products Regulatory Agency Concludes Positive Safety Profile For Pfizer/BioNTech’s COVID-19 Vaccine In 12-to-15 Year Olds

By Benzinga Newsdesk

Today, 7:22 AM

-Reuters-Reuters

BNTX

1 minute read

Medtronic Pulls Plug On Heart Implant Device Amid Growing Concerns Over Patient Safety

By Kate White

Today, 7:22 AM

Medtronic PLC (NYSE: MDT) announced Thursday that it is stopping the distribution and sale of the Medtronic HVAD System, an implantable heart pump, after numerous data indicated higher occurrences of adverse events, including stroke and mortality, as compared to other circulatory-support devices.

MDT

3 minute read

FDA
News

Novartis Says Co Reports Clinically Relevant Improvement In Median Overall Survival Data In Final Analysis Of Pivotal NETTER-1 Study With Targeted Radioligand Therapy Lutathera

By Benzinga Newsdesk

Today, 7:22 AM

Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus 30 mg octreotide LAR

NVS

4 minute read

FDA
News

AstraZeneca, Merck Report Results From OlympiA Phase 3 Trial Of LYNPARZA For Patients With Germline Breast Cancer Gene-Mutated High-Risk Early Breast Cancer Showed Statistical Significance, Clinically Meaningful Improvement In Survival

By Benzinga Newsdesk

Today, 7:22 AM

First medicine targeting BRCA mutations to show clinical benefit in adjuvant setting WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced

AZN

3 minute read

FDA
News

Bristol Myers Squibb Offers Date From CheckMate -648 Showing Opdivo Plus Chemo And Opdivo Plus Yervoy Improved Overall Survival vs Chemo In Unresectable Advanced Or Metastatic Esophageal Squamous Cell Carcinoma

By Benzinga Newsdesk

Today, 7:22 AM

Opdivo demonstrated significant overall survival benefit over chemotherapy alone in both PD-L1 positive and all-randomized populations in both treatment arms CheckMate -648 marks the third global trial in which Opdivo

BMY

26 minute read

FDA
News

Merck Says Co’s KEYTRUDA (pembrolizumab) Given After Surgery Reduced Risk Of Disease Recurrence Or Death By 32% Versus Placebo As Adjuvant Therapy In Patients With Renal Cell Carcinoma (RCC)

By Benzinga Newsdesk

Today, 7:22 AM

Merck's KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) KEYNOTE-564 is the

MRK

1 minute read

Why Senseonics Shares Are Rocketing Higher After Hours Thursday

By Chris Katje

Today, 7:22 AM

Study results from a glucose monitoring company were reported after market close Thursday.

ABT

3 minute read

FDA
News

NANOBIOTIX Reports New Data For Potential First-In-Class Radioenhancer NBTXR3 In Combination With Anti-PD-1 Showing Local Or Distant Tumor Regression In 76.9% Of Evaluable Patients Regardless Of Prior Anti-PD-1 Exposure

By Benzinga Newsdesk

Today, 7:22 AM

Data to be Presented at the 2021 Annual Meeting of the American Society for Clinical Oncology Results show NBTXR3 plus radiotherapy could potentially stimulate immune response and convert anti-PD-1 non-responders into

NBTX